Background 177Lu-octreotate may be used to deal with somatostatin receptor expressing neuroendocrine tumors. Hh and PI3K/AKT/mTOR pathways. Outcomes Sonidegib monotherapy led to inhibition of tumor development, while a substantial reduction in suggest tumor quantity was noticed after 177Lu-octreotate monotherapy and mixture therapy. Time for you to development was long term in the mixture therapy group… Continue reading Background 177Lu-octreotate may be used to deal with somatostatin receptor expressing